Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at Berenberg Bank

Berenberg Bank initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.60 target price on the stock.

A number of other equities research analysts have also recently commented on the stock. Truist Financial upped their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Friday, November 1st. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care currently has an average rating of “Moderate Buy” and a consensus target price of $24.30.

Fresenius Medical Care Stock Performance

Shares of FMS traded up $0.11 during midday trading on Wednesday, reaching $21.20. 53,169 shares of the stock were exchanged, compared to its average volume of 369,342. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. Fresenius Medical Care has a twelve month low of $16.86 and a twelve month high of $22.76. The business’s 50-day moving average price is $20.38 and its 200 day moving average price is $20.21. The company has a market capitalization of $12.44 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 0.97 and a beta of 0.91.

Institutional Investors Weigh In On Fresenius Medical Care

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP grew its stake in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares during the period. GAMMA Investing LLC grew its position in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after buying an additional 1,675 shares during the period. ORG Partners LLC purchased a new position in Fresenius Medical Care in the first quarter valued at about $110,000. ORG Wealth Partners LLC acquired a new stake in shares of Fresenius Medical Care during the 3rd quarter valued at approximately $112,000. Finally, Venturi Wealth Management LLC boosted its stake in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after acquiring an additional 4,800 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.